Subscribe   RSS Contact Us

Kamp Commentary: Pricing Issues Take Center Stage in D.C.

May 23, 2017 — By Coalition for Healthcare Communication Executive Director John Kamp Participants at last week’s Coalition for Healthcare ... read more

Califf Calls for Off-label Promotion Code of Ethics

May 18, 2017 – At this week’s information-packed Coalition for Healthcare Communication’s Rising Leaders Conference, keynote speaker and former FDA ... read more

The Marketing Implications of Tax Reform

By John Kamp, Coalition for Healthcare Communication Executive Director May 11, 2017 – Although no one seems to like the ... read more

Gottlieb Vote Headed to Full Senate

May 1, 2017 – Having cleared the Senate Committee on Health, Education, Labor and Pensions (HELP) with a 14-9 vote ... read more

What Medical Marketers Can Expect from President Trump, Republican-led Congress

April 24, 2017 – There is no doubt that the Trump administration is likely to change health policy, but the ... read more

Kamp: Three Ways Congress Could Suppress DTC or All Medical Marketing

Coalition Commentary by Executive Director John Kamp April 17, 2017 — Agencies, media and clients all need to watch closely ... read more

States Make Moves to Ease, Restrict Medical Communications

March 31, 2017 – With Congress in a seemingly permanent state of gridlock, individual states are taking actions that may ... read more

Previous Next

Author of “Pharmaphobia” Says Conflict-of-interest Regulations Are Slowing Medical Progress

June 8, 2015 – In his new book, “Pharmaphobia: How the Conflict of Interest Myth Undermines American Medical Innovation,” Tom Stossel, M.D., states that regulations designed to limit valuable interaction between industry experts, physicians and researchers have “undermined scientific progress and stifled American medical innovation.”

According to Stossel, the book has two purposes: (1) to explain what medical innovation has accomplished and how it works; and (2) to expose the “phamaphobes” who deny the contributions made by industry and “allege that industry is corrupt and corrupts physicians and researchers who partner with it,” and “explain why they are wrong and the damage they do.”

Stossel told the Coalition that this damage includes “prevention or delaying of research activities and outright banning of activities that promote medical education and good patient care,” such as providing product samples.

“Tom Stossel, a distinguished Harvard professor, provides a refreshing new view of the conflict-of-interest debate by asserting that the existing focus on conflicts rather than collaborations ultimately hurts medical innovation and clinical practice,” said Coalition for Healthcare Communication Executive Director John Kamp. “Stossel rightfully demands that it’s time to rethink and refocus the conflict of interest discussion.”

The book calls out “the false insinuation that the medical products industry and those who partner with it are corrupt, placing personal profit above providing medical value.” Stossel uses facts and figures to dispute this notion. He also does the following:

  • Documents how private industry is the major engine of medical innovation, but requires partnerships between industry, physicians, and universities.
  • Delineates the current and future damages such “conflict-of-interest” allegations, and the stifling regulations they have spawned, have done to medical innovation.
  • Prescribes how citizens wanting medical innovation and industry should resist the vested interests that have created the damaging allegations and regulations.

When asked specifically about the impact of the Physician Payments Sunshine Act, Stossel told the Coalition that the Sunshine Act “epitomizes the success the pharmaphobes have had in inappropriately demonizing industry and M.D.-industry partnership.” He added that “aside from being useless and insulting – and being a vehicle for shaming – it diverts billions of dollars from research, product development and education to compliance.”

Stossel, a visiting scholar at the American Enterprise Institute for Public Policy Research, is a hematologist and medical researcher at Boston’s Brigham & Women’s Hospital and Harvard Medical School. He will be interviewed by his son, Scott Stossel of The Atlantic, on Tuesday, June 16, from 6 p.m.-7 p.m. To watch live online, click here on June 16 at 6:00 p.m. ET. Registration is not required.

Policy and Medicine: News Outlets Accentuate the Negative in Describing Industry-Physician Relationships

April 4, 2013 — Headlines run by news outlets regarding the status of industry-physician relationships rarely focus on the benefits of those relationships, according to an April 3 article in Policy and Medicine. Instead, “news outlets are continuing their misleading headlines and stories regarding physician-industry collaboration over the last few weeks by relying on the recently updated payment

data posted by ProPublica and its Dollars for Docs campaign,” the article states. It outlines news coverage in five states from news organizations that used the Dollars for Docs database as the basis for their stories.

“Focusing on the negatives and ignoring the positives of industry-physician relationships is both misleading and detrimental to the public health,” said Coalition for Healthcare Communication Executive Director John Kamp. “The public and the press need to be aware that without these important and necessary collaborations, healthcare innovation and patient quality of life would most certainly suffer.”

To read the full story, go to:

Surgeon: Physician/Industry Collaboration More Likely To Advance Care than To Create Conflict of Interest

Dec. 10, 2012 – As the debate continues regarding the pros and cons of industry/physician collaboration, a British-born surgeon has suggested in an article that the recent push to curtail and constrain this important interaction fails to recognize the benefits it can provide to the public health, according to a recent post in Policy and Medicine.

“This article supports the Coalition’s view that when industry and physicians work together, their relationships often lead to new treatments and procedures that improve care and the quality of life for U.S. patients,” said John Kamp, Executive Director of the Coalition for Healthcare Communication. “Certainly the system needs to have safeguards, but to continue to thwart these collaborations would do much more harm than good.”

Indeed, the majority of doctors act solely with their patients’ welfare in mind, Dr. Jonathan Mark Sackier states in Human Events. “Recent legislation and hyperbole decreeing that physicians should have no dialogue with life science companies, should not receive royalties for inventions or fees for running clinical trials or delivering speeches and such activities due to concerns of ‘conflict of interest’ are blatantly absurd – in what other branch of human enterprise is effort not rewarded?” Sackier wrote.

Throughout the article, Sackier asserts that major medical breakthroughs in the treatment of many conditions, including cancer and diabetes, were the result of “Clinicians spotting an unmet clinical need, scientists who collaborated to solve a problem, financiers who took a chance, companies who invested time, money and resources.”

He wonders “why, exactly” anyone wants “to throw all of this away,” just because “certain individuals think certain physicians might use undue influence to pervert medical therapies.” He concludes that “doctors need to be allowed to have free discourse with their industry colleagues, the free speech guaranteed to all in our Constitution.”

To read Sackier’s article in Human Events, go to:

To read the Policy and Medicine post, go to:

ACRE Code of Conduct Statement Respects Value of Physician/Industry Relationship

Nov. 6, 2012 – The Association of Clinical Researchers and Educators (ACRE) recently published a statement to assist physicians as they navigate how to become involved appropriately in research, education or other collaborations with industry. This statement calls for careful consideration of collaborations, but also notes that these collaborations “have added considerably to patient care and have been conducted with integrity and commitment.”

ACRE wrote the guidelines “because we were getting concerned about the number of conflicting statements and comments being made about involvement by physicians in collaborations with industry,” said Michael Weber, M.D., Chair of the ACRE Writing Committee. “We wanted to give clinicians some basic ideas that they could use in making up their own minds about how to work on projects with companies.”

“All sectors should applaud these common-sense ideas because they enable doctors, educators and scientists to effectively collaborate with industry,” according to John Kamp, Executive Director, Coalition for Healthcare Communication.

ACRE states in its code of conduct guidelines that “the active and continuing collaboration of clinicians and industry is vital to patient care. … Many of the major therapeutic advances across the spectrum of medical practice during recent years have been linked to these collaborations.” The ACRE document includes recommendations for eight types of physician interaction with industry:

  • Clinical and scientific research
  • Consulting and advisory activities
  • Continuing medical education (CME)
  • Product-specific education
  • Publishing
  • Expert witness activities
  • Travel
  • Professional medical societies.

The ACRE Code of Conduct Guidelines span 25 pages (the document can be viewed in its entirety by clicking on the document name) and differ from the more stringent rules and bans established by the federal Sunshine Act, medical school deans and other organizations because they are based “on the premise that collaborations with industry [can] create medical progress that adds to the well-being of patients,” Dr. Weber told the Coalition.

Several of ACRE’s key recommendations, which are designed to ensure that physicians do not enter into industry relationships blindly and point out ethical issues that physicians must address, are listed here:

  • Physicians should be clear regarding the reasons underlying their research commitments and roles (Research);
  • Physicians should be clear about the distribution of funding to be provided by the outside source (Research);
  • When asked by industry to serve as public spokespeople, it is generally appropriate for faculty experts to explain scientific and clinical data arising from collaborative work in which they took part (Consulting);
  • Faculty members are strongly encouraged to participate in the planning of CME events, and in particular to ensure that they have control over the content of their presentations and are comfortable with their educational and scientific value (CME);
  • In deciding whether to join product-specific education programs, physicians should ask whether participation by faculty members provide teaching that ultimately contributes to patient care and should assert their independence and avoid the appearance of selling the product (Product-specific Education);
  • Physicians should ensure – before a study begins – that the decision to publish study findings will be made by them (Publishing);
  • Overall, it is appropriate to take the position that physicians should not accept money from industry for authorship (Publishing);
  • Physicians should ensure that travel support is used for legitimate reasons and that acceptance of travel support is not linked in any way to prescribing performance or other perceived endorsement of a sponsor’s product (Travel); and
  • There is a strong obligation for the leaders of medical societies to create internal operational procedures to ensure that their much-needed corporate support does not create inappropriate endorsements of industry products or give the appearance of doing so (Medical Societies).

ACRE also states in the document’s final notes that does not wish to continue the “disturbing trend” of using the terms “conflict of

interest” or “competing interests” when describing relationships between physicians and industry because they are “pejorative.” “Conflict of interest implies that a physician is being rewarded for an action that may not be in the best interests of science or medical progress,” Dr. Weber explained. ACRE prefers the term “acknowledgements of support” when making disclosures, according to the document.

A more balanced approach to monitoring physician-industry relationships appears to be warranted. A Policy and Medicine article discussing ACRE’s recommendations notes that “the absence of bias in CMA programs has been documented in three large studies and several surveys” (to view this article, go to: Dr. Weber remarked that “there is no real evidence of [problems] with CME. The unfortunate fact is that critics assume that the involvement of industry, by definition, is a bad thing.”

Authors of the ACRE guidelines disagree with this characterization. “We believe, if done right, everyone – patients, physicians and industry – benefit from the process,” Dr. Weber stated. “It is important, however, to follow the rules carefully, and we stress this in our guidelines.”

The ACRE guidelines are certainly a step in the right direction, according to the Coalition’s Kamp. “Creating reasonable standards for dealing with the relationship issues that does not call for relationship bans – or extensive paperwork having the effect of a ban – supports both the necessary transparency these relationships require and the value they bring to patients,” Kamp said.

Massachusetts to Hold Oct. 19 Public Hearing to Discuss “Modest Meal” Exception

Sept. 28, 2012 – Pharmaceutical and medical device companies may be allowed to provide “modest meals and refreshments” at non-continuing medical education (CME) events in Massachusetts if proposed “emergency amendments” to the state’s law covering codes of conduct for these industries are adopted. An Oct. 19 hearing is planned to discuss the amendments.

In July, state legislators passed revisions to the 2008 Pharmaceutical and Device Manufacturer Code of Conduct (PCOC) as part of the 2013 state budget.

The Massachusetts Public Health Council last week set forth an exception to the 2008 gift ban that would allow meals to be offered at non-CME presentations for healthcare professionals outside of the office or hospital setting.

The amendments set forth the following definition: “Modest Meals and Refreshments, food and/or drinks provided by or paid for by a pharmaceutical or medical device manufacturing company or agent to a health care practitioner that, as judged

by local standards, are similar to what a health care practitioner might purchase when dining at his or her own expense.”

The amendments also include the following provisions:

  • Pharmaceutical or medical device manufacturing companies and agents may provide or provide payment for modest meals and refreshments to health care practitioners outside of the health care practitioner’s office or hospital setting for the purpose of educating and informing health care practitioners about the benefits, risks and appropriate uses of prescription drugs or medical devices, disease states or other scientific information, provided that such presentations occur in a venue and manner conducive to informational communication. For the purposes of 105 CMR 970.006(3), “appropriate uses” may not include the promotion of off-label uses of prescription drugs or medical devices.
  • No pharmaceutical or medical device manufacturing company may provide or provide payment for such meals and refreshments permitted under 105 CMR 970.006(3) unless such pharmaceutical or medical device manufacturing company files quarterly reports detailing all non-CME educational presentations at which such meals or refreshments are provided. Reports shall include:
    • the location of the non-CME presentation;
    • a description of any pharmaceutical products, medical devices or other products discussed at such presentation;
    • the total amount expended on such presentation; and
    • an estimate of the amount expended per participant, factoring any meals, refreshments or other items of economic value provided at such presentation.

The amendments, which the Council has asked to be adopted on an emergency basis, also allow “for transparency through federal disclosures published in a searchable database by the DPH allowing monitoring of manufacturer conduct.”

The proposed amendments do not change the code of conduct regarding meals related to CME. The current provision stipulates that pharmaceutical or medical device manufacturing companies may not provide “payment for meals directly to a health care practitioner at any CME event, third-party scientific or educational conferences, or professional meetings, although a CME provider or conference or meeting organizer may, at its own discretion, apply any financial support provided by a pharmaceutical or medical device manufacturing company for the event to provide meals for all participants.”

According to the Massachusetts Public Health Council, the proposed amendments for non-CME events:

  • Are consistent with nationally recognized standards included in industry codes of conduct;
  • Promote educational and training opportunities;
  • Implement legislative intent to balance consumer protection, the legitimate interests of pharmaceutical and medical device manufacturers, and promoting the education of health professionals; and
  • Include a definition of modest meals and refreshments that does not include a specific dollar limit.

In addition to holding the Oct. 19 hearing, the Massachusetts Department of Public Health will be accepting written comments on the proposal. The regulation will be voted on by the Council at its Nov. 14 meeting and will be filed with the Secretary of the Commonwealth. The final regulation will be effective as published on Dec. 7.

“We are working with PhRMA and other allies on how best to participate in the upcoming Oct. 19 hearing,” said Coalition for Healthcare Communication Executive Director John Kamp. “Indeed, we are looking for input from members in comment form and would particularly like to hear from our members in Massachusetts.”

Although Several Sunshine Act Rules Remain Unsettled, Senate Roundtable Participants Largely Agree with Coalition on Major Issues

Review and Commentary by John Kamp, Executive Director, Coalition for Healthcare Communication

Sept. 17, 2012 – The only absolutely certain news coming out of the Sept. 12 U.S. Senate  Special Committee on Aging Roundtable on the Sunshine Act is that final rules are on their way. Within the next few years, all industry payments to physicians and researchers will be available on an Internet registry for the patients, press, policymakers to see and act on. However, the most important question is still unanswered: Will the registry support or hinder medical care and innovation?

The Roundtable participants reached considerable consensus on several of the key issues raised in the Coalition for Healthcare Communication Sunshine Act Comment sent to CMS on Feb. 15.  Most importantly, the Coalition stressed the importance of placing Sunshine Act data in context, so that all entities will understand that industry payments are vital and useful to the advancement of innovation and patient care in America.

“Without this context, CHC fears the reports will do more harm than good,” the CHC told CMS. “It would be a tragedy if these reports lead the public to misunderstand the complex interaction between scientific research and communication in both the creation and adoption of medical innovations.”

Although the Centers for Medicare & Medicaid Services (CMS) did not offer a glimpse of the final rules or provide any update regarding implementation dates, the CMS representative at the Roundtable – held to discuss the Sunshine proposed rule – made it clear that timely final rules are a priority and that industry would have additional time to put systems in place before data collection is required.

Niall Brennan, director, Policy and Data Analysis Group, CMS, said that he was “hopeful” that at least “some data collection will begin in 2013,” which sends a clear signal that the collection mandate will extend beyond Jan. 1, 2013.

(A detailed summary of the meeting can be found on the Policy and Medicine blog offered by Thomas Sullivan:

CMS’s flexibility on the deadlines was just one of the many good omens at the Roundtable. Virtually every participant understood the immense challenges facing the government, industry and the medical community to get this rule done right, rather than pushing for a final rule with vague provisions and impossible implementation deadlines.

Many of the stakeholders at the Roundtable agreed that the registry must not be used to discredit all industry relationships. Douglas Peddicord, Ph.D., executive director, Association of Clinical Research Organizations (ACRO), was the most articulate on this point at the Roundtable. Peddicord pointed out that all entities must remember that while payments denote “interest,” interests do not necessarily create conflicts of interest. “We need to remember that those interests need to be protected, because without interest by individual doctors, researchers and academia, there is no progress and innovation in medicine,” Peddicord said.

Peddicord made it clear that his was no theoretical concern, citing an ACRO study where 24 percent of researchers said they were less likely to engage in industry-sponsored research if the CMS proposed rule was put in place. He further warned that the United States could lose as much as half of its clinical research activity if the final rule did not limit the scope of the required disclosures.

Moreover, many Roundtable participants echoed the concern in the CHC comment that without clear rules to avoid errors, inconsistencies, and duplication – and a better error correction process – the registry often could be wrong and misleading. Elizabeth O’Farrell, senior vice president, Policy and Finance, Eli Lilly & Co., offered the best solution. She said clarity and accuracy would be greatly enhanced if CMS adopted a three-phased approach to implementation, giving industry and doctors at least 180 days to report the most frequent, direct and important payments, then phasing in some of the more difficult research and other payments at later dates. 

All participants asked CMS to offer a more practical approach to accounting for incidental items, especially food. .Indeed, calculating the cost of meals and other food provided at educational events – and determining whether specific individuals consumed them – was discussed in some detail at the Roundtable, with the majority of the stakeholders agreeing that administrating and monitoring this provision likely would consume more cost and time than is warranted. 

O’Farrell said the meal allocation methodology in the proposed rule is unworkable and inappropriate. Indeed, “nobody really cares about bagels,” said Charles Rosen, M.D., clinical professor of Orthopedic Surgery, University of California, Irvine School of Medicine, the most outspoken industry critic on the Roundtable. He encouraged a more reasonable final rule provision for meals and incidentals.

Mark McClellan, director, Engelberg Center for Health Care Reform at the Brookings Institution and moderator of the Roundtable, focused all participants on the hot-button issue of “indirect” payments, a significant area of concern noted in all industry and medical society comments.

For example, the Coalition encouraged CMS in its comments to reverse its broad inclusion of “indirect payments” despite their exclusion in the Sunshine Act. Speaking about CME, Jeremy Lazarus, M.D., president of the American Medical Association, explained to Rosen and others the difference between certified and promotional education and asserted that certified CME was intended to be excluded under the “indirect” exemption in the Sunshine statute.

In sum, the Roundtable discount cialis without prescription participants agreed that the CMS proposed rule is only a first step toward workable and clear implementation of the Sunshine Act.

Many of the additional steps must be taken by us. CMS will do its best to follow the letter and intent of the statute, and may even help to advance the public understanding of the data.

But most of that burden will have to be carried by industry and, in particular, by industry and its communication partners. We still have a long way to go to do our part after the registry is out to ensure that its data and the underlying importance of industry partnerships is fully understood not only by patients,

but by doctor collaborators, policymakers and the press.

ACCME Annual Report Shows Decline in Industry CME Funding

July 30, 2012 – A report released last week by the Accreditation Council for Continuing Medical Education (ACCME) shows that the pharmaceutical industry’s funding of CME programs continued to decline in 2011. This trend is likely to continue if regulations to implement the “Sunshine” provisions of the Affordable Care Act proceed as proposed, and could

put an increasing number of patients at risk.

The 2011 ACCME Annual Report Data show that industry support for CME dropped by 11.4 percent, which equates to almost $94 million less spent on CME in 2011 than in 2010. This decline marks an ongoing shift away from industry as the primary supporters of CME activities. In 2007, industry funding represented 46 percent of total funding, but in 2011, industry funded only 32 percent of CME activities.

“The decline in commercial support for medical education demonstrates the folly of over-regulation. While the covered patient population continues to expand and the effective use of medicines is key to efficient and appropriate delivery of care, public policy makers should be developing rules and policies that encourage, not discourage, commercial support for doctor education,” said John Kamp, Executive Director of the Coalition for Healthcare Communication. “Transparency is a laudable goal,  knee jerk journalism and regulatory over reaction have moved us in the wrong direction.”

Although total income from CME was down 1.1 percent in 2011, income from advertising/exhibits at CME events and “other income,” which included registration fees and funds that came from a provider organization, did help the balance sheet. For publisher/medical education companies, income from CME activities was up 2.4 percent in 2011.

Non-physician attendance in CME events increased by 1 percent, while physician attendance decreased by .05 percent. Overall, publishing/education companies drew the most physician participants, with medical schools and hospitals/health care delivery systems rounding out the top three, according to the report. ACCME notes that its data for 2011 excludes in-kind support for CME and includes state and regional CME statistics.

This downward trend in industry CME spending is unlikely to be reversed by additional burdens imposed by Sunshine provision proposed regulations, the specter of which already may be dissuading health care providers from participating in

CME. Further, if the proposed regulations – which call for CME providers to report the value of education provided for each certified CME program attendee and would mandate that industry value and report each company-sponsored education and research activity – are published as proposed, they could further suppress both CME funding and participation.

“Regardless, I hope the final rules from HHS on the Sunshine Act will be much more sensible than the draft proposals. The industry, including PhRMA, BIO, AAFP, AMA, the Coalition and others have given them a much more sensible road map to effective but more sensible regulation,” Kamp continued. “Meanwhile, let’s take this week’s decision by Massachusetts regulators to kill the ban on drug coupons as a step in the right direction, and applaud similar steps.”

Guest Column: Heavy Meddle by Peter Pitts

May 7, 2012 — The American Recovery and Reinvestment Act (aka, “the stimulus package”) provided AHRQ with $29.5 million for a program on academic detailing and the “communication of CER results to physicians.”

One contract, for $11.7 million, went to Total Therapeutic Management (TTM) and is specifically intended for physician outreach and education.

(TTM is a company that focuses on chart abstraction, data mining, and physician and patient education for a predominantly commercial client base – health plans, pharmacy benefit managers, employers, and pharmaceutical companies, etc.)

The goal of this contract is to integrate AHRQ’s comparative effectiveness research, products, and tools into clinical practice through 9,000 on-site, face-to-face visits with clinicians, nurses, health plan formularies, benefit managers, and other healthcare professionals.

I recently interviewed the Barry Patel, the president of TTM.  Here are some snippets from our conversation:

How will the government decide which doctors are to be visited? Will “high prescribers” of on-patent medicines be on a priority list?

TTM’s top priority is “high volume” practices across 150 Metropolitan Statistical Areas (MSAs). So, rather than focusing on offices with disproportionately high negative patient outcomes, the government is directing its efforts against those doctors who are high prescribers – which is a pretty good indicator about what government detailing is all about – decreasing cost rather than improving care.

When it comes to government detailing (at the taxpayers’ expense), what are the metrics for success?

According to Mr. Patel, the only metrics are whether or not a physician says the sessions have been useful and asks the detailer to come back to discuss other topics. In other words, the metrics are subjective and anecdotal – not clinical.

Interestingly, Mr. Patel doesn’t even agree with either the term academic detailing or counter detailing. “We aren’t counter anything. We’re not there to undo anything. It’s not good versus bad. Our visits aren’t details, they’re the beginning of a process.” And, as far as “academic” goes, Mr. Patel uses that term because “that’s the phrase AHRQ uses and placed in the contract. Our people are patient-centered outcomes consultants, PCOCs.” And “his people” are largely pharmacists and nurses.

A former Merck employee, Patel likens his PCOCs more to pharmaceutical company Medical/Science Liaisons (MSLs) than field representatives. “They’re not discussing product-specific information, but the findings of comparative effectiveness studies.”

How does TTM schedule their appointments with targeted physicians?

According to Mr. Patel, when his “outreach experts” phone physicians to request appointments, the fact that the meeting will result in CME credits is always mentioned. Would a pharmaceutical company be permitted to offer such an enticement? Would such an offer be “sunshine-able” under state and federal guidelines? And, if so, why don’t government detailers have to share the details of their valued benefactions?

Interestingly, according to the Accreditation Council for Continuing Medical Education (ACCME), government is exonerated from having a commercial interest. (A commercial interest is any entity producing, marketing, re-selling, or distributing healthcare goods or services consumed by, or used on, patients.)

Our nation’s single largest payer, Uncle Sam, is not deemed to have a conflict of interest when it comes to designing and providing physician CME.

What’s wrong with this picture?

[Editor’s Note: Peter Pitts is president and co-founder of the Center for Medicine in the

Public Interest. This article appeared May 3 on Read more from Pitts on Government Detailing.]

New Video Highlights Advances in CME Conflicts of Interest Policies

March 19, 2012 – A new video produced by CME Peer Review – “Conflict of Interest: The Bottom Line” – features Coalition for Healthcare Communication Executive Director John Kamp and other continuing medical education (CME) experts who are moving ahead with strategies to minimize CME conflicts of interest.

Highlights of the video are discussed in a March 19 article in Policy and Medicine, where Kamp is quoted. In the article, Kamp states that CME stakeholders “have gotten the message” on conflict of interest disclosures and that “CME is the solution to many problems in our health care system because CME can help improve the delivery of efficient and effective health care to patients.”  Read the full article and access the video by clicking on this link:

Coalition Calls for Substantial Revisions to Sunshine Act Proposed Rules

Feb. 16, 2012 – Further notice and comment are necessary for the implementation of Section 6002 of the Affordable Care Act – known as the “Sunshine Act” – to ensure that the data submitted under the Act are accurate and are placed in the proper context for public understanding, according to the Coalition for Healthcare Communication Sunshine Act Comment submitted to the Department of Health & Human Services (HHS).

“Although the Coalition understands the importance of  transparency, there are numerous issues that need to be resolved – and further commented on by all stakeholders – if the rule is to fulfill its intended purpose,” said Coalition Executive Director John Kamp. “To get transparency right, the HHS must do a further notice on accuracy and context,” he asserted.

The Coalition is concerned that the current proposal would have a chilling effect on important collaborations between industry and healthcare providers, lead to unnecessary and significant complexities, increase costs and create public perception issues. These concerns “must be addressed fully before final rules are adopted,” according to the Coalition comment.

“Rubber-stamping the proposal as written would be a huge mistake that, ultimately, would hurt, rather than protect, patients,” Kamp noted, adding that the public perception issues are particularly important.

“It”s time for the press and some politicians to stop treating every reported payment as a newly uncovered scandal,” he said. “The real scandal is the demonization of collaborations between industry, academia and government. Collaboration has enabled the great medical breakthroughs that have added 10 years to the average American life in just a generation.”

In addition to the call for a further notice on accuracy and context, the Coalition’s comments focus on several areas needing additional refinement and review, and make the following recommendations:

  • HHS should hone the rules to more accurately reflect the legislative intent and the specific language of the statute, and “narrow its burdens and reach” accordingly. The Coalition cites indirect payments and vital prescriber education as examples of how HHS has expanded its purview under the proposed rule.
  • HHS should take a closer look at the costs associated with the proposal, including the significant cost of industry and provider compliance. The Coalition believes that HHS has underestimated the direct compliance costs and largely ignored the indirect “intangible costs of possibly misleading patients, caregivers and professionals regarding the nature and value of these relationships.”
  • HHS should clarify explicitly in the final statement of the rule that  commercially supported meetings and educational enduring materials are not intended to be covered by the statute and are not subject to any reporting requirement.

Further, because many details of the proposed rule are unknown, the Coalition is concerned that entities involved in the medicines industry will simply avoid many collaborative programs that provide healthcare providers with valuable professional education. Such a result “would harm, not help, patients,” Kamp said. “There is a lot more work to be done.”